An Unusual Presentation of Erythropoietin-Induced Acute Monoarthritis in a Patient With Myelodysplastic Syndrome and Behçet Disease: A Case Report.
Ouamer Ilham I, Belkhadir Samia S, Berkchi Moulay Jihad MJ, Achemlal Lahsen L
Helvetic Biopharma · EPOR · 重组蛋白
erythropoietin 是一种重组蛋白,由Helvetic Biopharma研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。
| 公司 | Helvetic Biopharma |
| 药物类别 | 重组蛋白 |
| 分子靶点 | EPOR |
| 给药途径 | Injectable (Others) |
| 状态 | Approved |
erythropoietin 作用于 1 个分子靶点:
| EPOR | erythropoietin receptor (EPO-R) |
erythropoietin 针对 1 个适应症,涉及 1 个治疗领域。
| 治疗领域 | 疾病/病症 | 分期 |
|---|---|---|
| Vascular disorders | Thrombosis | ✓ Approved |
Ouamer Ilham I, Belkhadir Samia S, Berkchi Moulay Jihad MJ, Achemlal Lahsen L
Palika Ravindranadh R, Chilumula Monica M, Dasi Teena T, Banjara Santosh Kumar SK et al.
A substantial proportion of anemia is not associated with iron deficiency (ID), particularly in India. However, the aetiology of anemia without ID remains elusive. To compare erythropoietic activity markers (erythropoietin, erythroferrone), micronutrient profiles, and inflammatory markers across four mutually exclusive groups of anemia and iron deficiency (ID) status: anemia with ID, anemia without ID, no-anemia with ID, and no-anemia and no-ID, to identify the factors associated with anemia without ID. In this cross-sectional study, pregnant women in their third trimester (n=687) were screened for complete blood count including hemoglobin, plasma ferritin (PF), soluble transferrin-receptor (sTfR), high-sensitive C-reactive protein (hsCRP) and Alpha-1-Acid Glycoprotein (AGP), vitamins B12, A, D and red blood cell-folate and in a sub-sample hepcidin, erythropoietin (EPO) and erythroferrone (EFRE) levels were measured. Anemia was defined when Hemoglobin <11g/dL and ID was defined when inflammation adjusted PF levels <20μg/L. The prevalence of anemia with ID, anemia without ID, no-anemia with ID and no-anemia and no ID were 26%, 21%, 11%, 42%, respectively. The anemia with ID group exhibited significantly lower mean Hb (9.32g/dL; 95% CI: 9.1, 9.5 Vs 10.08g/dL 95%CI: 9.9, 10.2), EFRE (0.55ng/mL, 95%CI: 0.5, 0.7 Vs 0.19ng/mL 95%CI: 0.1, 0.3) and higher median EPO (28.18mIU/mL; IQRs: 22.7, 41.0 Vs 22.00mIU/mL; IQRs: 20.8, 24.5) compared to anemia without ID group. Furthermore, despite lower hemoglobin, median EPO in anemia without ID was comparable to non-anemic groups. Micronutrient or Inflammatory markers were either similar or did not show consistent trends across the four groups. Further, hemoglobin levels showed significant negative correlation with EPO (r=-0.55, p<0.001) in anemia with ID group, but not in anemia without ID group (r=0.11, p=0.438). Our study findings suggest that reduced erythropoietic signalling may underly anemia without ID, which is not explained by inflammation or micronutrient deficiencies. Thus, diagnosing ID is vital for effective iron treatment.
Gadassi Noa N, Goldstein Sivahn S, Wulkan Michal M, Grinblatt Eynit E et al.
Objectives: To compare the effects of two different erythropoiesis-stimulating agents [ESAs] and no treatment on the number of blood transfusions and hematocrit [Hct] level. Methods: A retrospective study. Kaplan Medical Center provided data on ESA-treated infants, comparing erythropoietin [EPO] given per protocol until 2018 and darbepoetin [DPO] given from 2018 onwards. Meir Medical Center's data formed the control group. Data regarding ESA treatment were extracted from a computerized prospective database. A comparison of Hct levels at birth, 14 days of age, 1 month and before discharge and number of blood transfusions received during hospitalization was performed. Mean and standard deviation or median and interquartile range were used for continuous variables and frequency tables for categorical variables. Results: In total, 248 premature infants born between 2016 and 2021 under 1250 g, who survived beyond two weeks of age, were included. No significant differences were found between the EPO and DPO groups in terms of number of blood transfusions or Hct values. The control group received more blood transfusions after two weeks of age [0.8 ± 1.5 vs. 0.5 ± 1.2, p-value = 0.02]. In the treated group, higher Hct values were observed at one month of age [29.9 ± 4.2 vs. 37.9 ± 5.3, p-value < 0.01] and at discharge [29.7 ± 3.8 vs. 34.1 ± 4.6, p-value < 0.01] compared to the control group. Conclusions: ESA treatment was associated with higher hematocrit levels, and no significant differences in efficacy were found between EPO and DPO.
Choi Jaehyun J, Xu Enzhen E, Park Sihyun S, Woo Minji M et al.
Artificial intelligence (AI) is advancing nanomedicine development by linking formulation variables and biological context with delivery, therapeutic efficacy, and safety. This review examines AI assisted formulation design, centralized formulation databases, prediction of nanoparticle self assembly, and models of cell and tissue selective delivery, biodistribution, and therapeutic outcomes. Recent advances in predicting nanotoxicity and nanoparticle induced immune responses further emphasize the importance of incorporating safety endpoints into nanomedicine optimization. Beyond nanocarrier engineering, foundation models and multimodal analyses of single-cell and spatial data are expanding biological discovery by characterizing disease associated cellular states, prioritizing therapeutic targets, and predicting treatment responses. Computational approaches also support the design of therapeutic RNA, peptides, proteins, and programmable protein nanomaterials. For example, mRNA sequences generated by GEMORNA and delivered via lipid nanoparticles increased erythropoietin expression in mice by up to 15-fold compared with a benchmark sequence. Integration of biological discovery with biomolecular and nanocarrier design may inform therapeutic cargo selection, targeting strategies, and functional nanomaterial development. AI may connect patient specific biological characteristics with predictions of nanomedicine delivery and therapeutic response to support patient stratification and individualized treatment selection. Integration of histological, imaging, molecular, and longitudinal data may enable treatment strategies to be adapted to differences in tissue characteristics, disease state, and therapeutic response. Emerging approaches based on digital twins and adaptive treatment control may extend the framework toward individualized dosing and dynamic treatment optimization. Major challenges include data heterogeneity, limited model generalizability, and the need for experimental and prospective validation. Progress toward precision therapy will require integrated frameworks that jointly consider delivery, efficacy, selectivity, and safety while clearly distinguishing demonstrated applications from future opportunities.
Mjery Yahia A YA, Abdalla Saif Elden B SEB, Elsayed Tagwa Y TY, Alamer Edrous E et al.
Background/Objectives: Thyroid hormone regulates erythropoiesis, but most population studies have used thyrotropin (TSH) alone and have not examined whether the erythroid association differs by red cell phenotype. We examined this in a population where inherited microcytosis and iron deficiency are both common. Methods: We analyzed 3871 adults of both sexes with paired free triiodothyronine (FT3), free thyroxine, TSH, and complete blood count from three hospitals in Jazan, Saudi Arabia (3673 with FT3 within the reference interval formed the primary analysis). All three analytes were entered simultaneously in models adjusted for age and sex; mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) were pre-specified comparison (negative control) outcomes; red cell discriminant indices were used to assign a normocytic, acquired microcytic, or presumed inherited-trait pattern, which was compared against linked ferritin and transferrin saturation. Results: FT3 was associated with erythrocyte count (standardized β 0.097, 95% confidence interval (CI) 0.066-0.128, p < 0.001) and hemoglobin (+2.7 g/L per pmol/L); TSH was not (p = 0.547). The erythrocyte count association was present in normocytic (β 0.101) and acquired microcytic records (β 0.099) but absent in the presumed trait pattern (β -0.017; interaction p = 0.002) and remained absent under a stricter trait definition, whereas the hemoglobin association did not differ by phenotype (interaction p = 0.639). FT3 was unrelated to iron status, and the association survived adjustment for ferritin and restriction to same-episode iron measurements. In an exploratory comparison, both associations were strongest in iron-replete normocytic patients (hemoglobin +3.6 g/L per pmol/L, p < 0.001) and attenuated in measured iron deficiency. Conclusions: FT3, not TSH, was associated with erythrocyte count and hemoglobin. The count association was absent in the index-defined trait pattern, in which erythrocyte number is already high, and both associations were blunted where iron was limited. These observations are consistent with, but do not demonstrate, a limit on the marrow's count response, since erythropoietic activity was not measured; they are hypothesis-generating and require replication with confirmed hemoglobin genotype, measured iron status, and reticulocyte or erythropoietin data.
Lavanchy Luc L, Rohrer Felix F, Ltaief Zied Z, Othenin-Girard Alexandra A et al.
Background/Objectives: Anemia is a common condition in cardiac surgery and is strongly associated with adverse outcomes, including higher transfusion requirements, increased morbidity, and prolonged hospital stay. Enhanced Recovery After Surgery (ERAS) and Patient Blood Management (PBM) are both multimodal strategies designed to improve perioperative care. This study evaluates the impact of integrating ERAS and PBM with preoperative anemia management into a single standardized pathway in elective cardiac surgery. Methods: We conducted a retrospective, single-center before-after study at Lausanne University Hospital, comparing a pre-ERAS cohort (2019) with a prospective cohort managed under the ERAS-PBM pathway (May 2023-November 2024). The ERAS-PBM pathway included systematic preoperative anemia screening and treatment, reinforcement of adherence to existing restrictive transfusion thresholds, optimized blood conservation techniques, and standardized perioperative care bundles coordinated by a dedicated ERAS nurse. The primary outcome was the rate of red blood cell (RBC) transfusions during hospitalization. Secondary outcomes included overall transfusion rates, hemoglobin levels, complications, and length of stay. Results: A total of 391 patients were included (ERAS, n = 229; pre-ERAS, n = 162). RBC transfusion rates were significantly lower in the ERAS group (23.6% vs. 38.9%, p = 0.0012), with a reduction in the number of units per patient (p = 0.0005). Hemoglobin at admission was higher in the ERAS cohort (139.5 vs. 134 g/L, p = 0.0009). Overall complication rates decreased (46.3% vs. 66.7%, p < 0.0001), including major adverse cardiovascular events and pulmonary complications. Hospital stay was shorter (9 vs. 12 days, p < 0.0001), as was mechanical ventilation time (0 vs. 2.1 h, p < 0.0001). Anemic patients at admission were more transfused (39.3% vs. 18.6%, p = 0.002). Within the ERAS group, RBC transfusion was associated with higher rates of selected postoperative complications and longer ICU and hospital stays. In an exploratory multivariable logistic regression analysis, ERAS-PBM implementation was associated with lower odds of RBC transfusion during hospitalization (adjusted OR 0.59, 95% CI 0.36-0.98; p = 0.041). Conclusions: The integration of ERAS and PBM into a single multimodal pathway was associated with significant reductions in transfusion rates, complications, and length of stay in elective cardiac surgery. Anemia at admission and perioperative transfusion were associated with worse outcomes, emphasizing the importance of anemia management. Larger, multicenter prospective studies are warranted to confirm these results and to optimize anemia correction strategies, including earlier treatment of iron deficiency and outpatient erythropoietin use.
注册免费账户还可查看另外 9996 篇文献
免费注册查看全部文献 →